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Background and Aim of the Project 
 
Primary immunodeficiency (PID) diseases are heritable disorders of the 
immune system (1).  The field of the clinical description, genetic 
characterization, and immunological investigation of novel PIDs was born in 
the 1950s, but remains in its infancy, with considerable potential for growth 
(2).  One can even predict that most specialties in human medicine will benefit 
considerably from the expansion of PIDs, as immunity at large is central to 
physiology and pathology, because most tissues are subject to environmental 
assaults and contain myeloid and lymphoid cells (2). 
 In this context my PhD program has been focused to the study of some of 
these diseases in order to clarify “Novel Aspects in Immunodeficiencies”. 
Disruption of any part of the orchestrated immune response can result in 
an inability to control infections and subsequent illness. Apart from physical 
barriers, the immune response is composed from a diverse network of 
defenses, including cellular components and soluble mediators. A proper 
immune response relies on the innate immunity, characterized by a rapid and 
nonspecific initial response to infections and later on the adaptive immunity, 
characterized by a specific response to a particular antigen. The innate 
immune response involves three major cell types: phagocytic cells, such as 
neutrophils and macrophages, natural killer (NK) cells and antigen presenting 
cells (APC), which are also involved in the induction of an adaptive immune 
response. The adaptive immune system includes T and B lymphocytes 
responsible for cellular and humoral responses, respectively.  However, these 
components of the immune system act in a well orchestrated and integrated 
unique system in order to maintain a normal resistance to infections. 
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In the last 5 decades, since the first human genetic defect was identified 
more than 200 PID syndromes have been described.  PIDs can be divided into 
subgroups based on the component of the immune system that is 
predominantly affected, including T, B, NK lymphocytes, phagocytic cells 
and complement proteins. The antibody deficiencies (B‑ cell or humoral 
immunodeficiencies) are characterized by genetic lesion, that selectively 
affects antibody production, but a normal cell-mediated immunity. In the 
cellular deficiencies, cellular effector mechanisms are compromised, whereas 
antibody production is largely normal in that B‑cell intrinsic machinery is 
intact. The combined immunodeficiencies are characterized by an impairment 
of both effector arms of the specific immunity, which results in a more severe 
clinical phenotype.  However, since an efficient B-cell antibody response also 
depends on T-cell activation of B lymphocytes, defects in either cell type 
have the potential to affect both cellular and humoral immunity to varying 
degrees.  Of note, most of the diseases within the last category are due to 
genetically determined blocks in the T-lymphocyte differentiation program. 
In the absence of mature T-cells, adaptive immunity is abrogated, thus 
resulting in a broad ‑ spectrum susceptibility to multiple pathogens also 
including opportunistic microorganisms. Overall, irrespectively of the 
pathogenic mechanism of the individual form of severe combined 
immunodeficiencies (SCIDs), a common hallmark of these diseases is the 
feature that bacterial, viral and fungal infections are often overwhelming.  The 
discovery of a so wide number of distinct clinical entities which differ in 
either the genetic cause or the altered immunological function led to an 
incomparable increase in the knowledge of the intimate mechanism by which 
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a proper immune response is generated.  Intriguingly, most of the genes whose 
alterations underlie PIDs are selectively expressed in hematopoietic precursor 
cells (HPC) with a few exceptions as, for example, Ataxia Telangiectasia 
Mutated (ATM) gene, also expressed in Purkinje cells and Adenosine 
Deaminase (ADA) which is ubiquitous. This dogma, however, led to 
underestimate those novel immunodeficiencies, which have different features 
involving other nonhematopoietic tissues. 
This thesis reports the results I obtained during my PhD course in “Human 
Reproduction, Development and Growth” (XXII Cycle) from 2006 to 2009.  
During the past 3 years, my research has been focused in the study of the 
following 5 lines of research: 
 Role of common gamma chain (gc) (X-SCID causing gene) in 
Growth Hormone Receptor signaling defining the basis of the physiological 
interaction between Endocrine and Immune Systems; 
 Intrinsic property of gc as a key molecule in the cell cycle 
progression, spontaneous or GH-induced, its role being strongly related to its 
cellular amount;  
 Molecular and clinical characterization of the human 
Nude/SCID phenotype and identification of clinical signs suggesting a 
previously unappreciated functional role of FOXN1 transcription factor in the 
development and differentiation of the central nervous system; 
 Effects of steroid  treatment in patients affected with Ataxia 
telangiectasia and the role of oxidative stress in its beneficial consequence; 
 New insights in the T-cell ontogeny defects, studying different 
mechanisms or molecular alterations influencing both positive and negative 
selection processes. 
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CHAPTER 1  
The X-linked Severe Combined Immunodeficiency 
 
Severe Combined Immunodeficiencies (SCIDs) represent a wide spectrum of 
illnesses, which differ in either the qualitative or quantitative alterations of T, 
B and NK cells (1).  Most forms of SCID are associated with molecular 
alterations of genes selectively expressed in hematopoietic cells and 
implicated in cell differentiation/activation process.  Mutations in nine 
different genes have been found to cause the human SCIDs.   
The products of three genes, such as interleukin-2 receptor gamma 
(IL2RG), Janus associated kinase 3 (JAK3), and IL7R are components of 
cytokine receptors, while the products of RAG1, RAG2 and ARTEMIS are 
essential for antigen receptor gene rearrangement.   
The most common form of SCID accounting for approximately half of all 
cases, with an estimated incidence of 1:150000 to 1:200000 live births is the 
X-linked severe combined immunodeficiency (X-SCID) (2-3).   
This form of SCID is characterized by the absence of mature T and NK 
lymphocytes and absent immunoglobulin synthesis, despite the presence of a 
normal or sometime elevated number of B cells.  In X-SCID patients, T cells 
are absent not only in the peripheral blood but also in the central and 
peripheral lymphoid organs suggesting an early block in the T-cell 
differentiation pathway (4).  Furthermore, although peripheral B cells exhibit 
a normal phenotype, X-SCID patients B cells are not functional, even after T-
cell reconstitution by means of bone marrow transplantation (5-6). 
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§ 1.1            X-linked Severe Combined Immunodeficiency:  
              the gamma chain transducing element 
 
The most common form of SCID is the X-linked form that accounts for 40–
50% of all cases.  This form is frequently caused by alterations of the IL2RG 
gene that encodes for the common cytokine receptor gc, a shared component 
of several cytokine receptors.   
A wide range of cytokines have been molecularly recognized.  They are 
soluble elements that control the immune and the hematopoietic system (7).  
Their pleiotropic and redundant functions are due to the various receptors 
expressed on multiple target cells, so, cytokines’ specific rules are closely 
dependent on the recognized targets.  Therefore, for appreciating such 
cytokine functions, a lot of cytokine receptors have also been molecularly 
studied and characterized.  These are classified into five families, created on 
the bases of extra- and intra-cellular domains structure affinity: the cytokine 
receptor superfamily, interferon receptor family, TNF (Tumor Necrosis 
Factor) receptor family, TGF (Tumor Growth Factor)-breceptor family, and 
IL-8 (Interleukin-8) receptor family (8).  The cytokine receptor superfamily is 
the largest family, containing no less than 18 different receptor molecules, a 
quantity of which may be included among multiple cytokine receptors; the 
receptors for IL-6, IL-11, OSM, CNTF, and LIF contain the common gp130, 
and the receptors for IL-3, IL-5, and GM-CSF enclose the common gc.  
Essentially, gc and gp130 contribute to increase the ligand-binding affinity 
and to establish an intracellular signal transduction (8-9).  
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The gc is a component of several receptors such as for IL-2 receptor (IL-
2R), IL-4R, IL-7R, IL-9R and IL-15R.  To our knowledge, an 
extrahemopoietic role of gc has not yet been demonstrated, although the 
abundance of the protein in nonhemopoietic cells would imply additional 
functions for this element (10-11).   
The signals, that are dependent on gc, have been shown to be important for 
various immunological function.  The characterization of cytokine-activated 
genes, including genes regulated by gc-dependent cytokines, has long been an 
area of considerable interest, although only few systematic studies have been 
conducted.  These studies have now allowed the identification of gene 
expression programs involved in complex biological processes including 
studies regarding genes induced by gc-dependent cytokines (12-13) and of 
changes in gene expression that take place during T-cell differentiation either 
in Th1 or Th2 conditions (14).    
Even though the role of different cytokine-dependent signaling pathways 
in the regulation of gene responses is still unresolved, there are a wide variety 
of evidences that the common cytokine receptors gc cytokines control the 
immune response at different as well as overlapping checkpoints, and their 
expression levels are diversely controlled during an immune response (Table 
2).  In fact, IL-2, IL-7 and IL-15 were reported to regulate a highly 
overlapping set of more than one hundred genes, exerting diverse effects 
correlated to T-cell survival, activation and clonal expansion, and to the 
development and preservation of cell memory.  Moreover, IL-7 regulates 
lymphocyte development and homeostasis.  Furthermore, an important role 
for IL-7 in T- and B-cell development was first suggested by experiments in 
which B- and T-cell development was abrogated when mice were injected 
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with antibodies to either IL-7 (15-17).  In fact, IL-7 has an action based on an 
increase of cell survival correlated to an induction of Bcl-2 gene expression.  
However, other cytokines such as IL-15 and IL-2 may be more important.  In 
fact, although IL-7R is highly expressed on resting T cells, it is rapidly 
downregulated by T cell Receptor (TCR) stimulation as well as by IL-2, 
further supporting the idea that other cytokines are more relevant for effector 
functions (18).  In particular, both IL-2 and IL-15 are T-cell growth factors in 
vitro, and they can stimulate the proliferation of NK cells as well as induce 
NK cell cytolytic activity. However, important in vivo differences in the 
actions of these two cytokines have emerged, particularly, in regard to NK cell 
development and CD8b T-cell homeostasis (19).  As noted, IL-2Ra deficient 
mice show generally normal T, B and NK cell development. However, Il-2rb-
deficient mice have profoundly decreased numbers of NK cells and g/d T 
cells, suggesting that IL-15 but not IL-2 is necessary for the 
development/differentiation of these cells. Indeed, mice deficient in either Il-
15 or Il-15ra lack NK cells, confirming the distinctive role for IL-15 in NK 
cell development (20-21).  Thus, IL-15 is essential for the homeostatic 
proliferation of memory CD8+ T cells and maintenance of the steady-state 
level of CD8+ T-cell memory, exerting, furthermore, direct effects on 
memory CD8+ T cells and on other cell types, which subsequently control 
memory T-cell proliferation.  On the other hand, IL-9 is a mast cell growth 
factor and was first identified as a late-acting T-cell growth factor and mast 
cell growth factor.  Il-9-deficient mice have also been generated, and the 
lymphoid compartment develops normally in these animals.  However, these 
mice exhibit excessive mucus production and mast cell proliferation (22).  
But, such abnormalities have not been reported in humans with X-SCID, 
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suggesting that the gc isn’t responsible of this phenomenon.  Interestingly, Il-9 
transgenic mice develop thymic lymphomas, consistent with the presence of 
Il-9 receptors in the thymus and with the ability of thymocytes to respond to 
Il-9.  Instead, roles of IL-4 and IL-21 in Th-cell differentiation and 
immunoglobulin (Ig) Synthesis Gene knockout models of different gc-
dependent cytokines have revealed roles for IL-4 and IL-21 in the regulation 
of Ig production. Early work had indicated a role for IL-4 in B-cell Ig class-
switch to IgG1 and IgE (23).  
It is now clear that gc cytokines regulate several aspects of immune 
activation, they play an important role in supporting survival, proliferation and 
effector functions of activated immune cells.  Clearly, regulation of cell 
survival and cell apoptosis is a delicate teamwork and a balanced act of all gc-
dependent cytokines is of central importance.  Thus, abnormality of either one 
of them can have a profound impact on the homeostasis of the immune 
system.  Undoubtedly, a balanced act of gc-cytokines is critically important in 
this regard.  However, given the widespread use of gc among cytokine 
receptors, this pathway is likely to have implications for anti-apoptotic 
signaling in a variety of contexts (24). 
Ursini et al. in 2002 reported on a patient affected with X-SCID, due to gc 
alteration, who received a bone marrow transplantation late at 5.2 years of age 
(25).  In this patient, short stature became evident and a peripheral growth 
hormone (GH) hypo responsiveness associated with abnormalities of the 
protein phosphorylation events that occur following GH receptor (GHR) 
stimulation was demonstrated.  After this observation, since that the 
abundance of gc in non hematopoietic tissues was largely demonstrated, we 
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hypothized that the GH hypo responsiveness was due to the hematopoietic 
alteration. 
The potential role of gc in GHR signalling was assessed using B cell lines 
(BCLs) from healthy control and gc-negative X-SCID patients.  In particular, 
the authors demonstrated the impairment of gc in various GH-induced events.  
At first, the role of gc became evident, by proliferation assay, in the functional 
response of both kinds of cells to GH in a dose-dependent manner.  In fact, 
GH enhanced proliferation of control BCLs in a dose-dependent fashion.  By 
contrast, the functional response to GH of the BCLs of gc-negative patients 
was severely impaired despite a comparable cellular expression of GHR 
molecules. 
Furthermore, the signal transduction properties of GHR in X-SCID 
patients and control BCLs following GH stimulation was also examined by 
analyzing the pattern of protein tyrosine phosphorylation.   The activation of 
JAKs and STATs represents a prominent biochemical event during GH-
dependent proliferation of lymphoid cell lines (26).  Other signaling pathways 
also contribute to a full GHR response, in fact, GH has been shown to activate 
the PI3K protein kinase B signaling (27), MAPKs, and ERKs 1 and 2 (28-30).  
In contrast to what observed in control BCLs, in X-SCID patients GH 
stimulation failed to induce phosphorylation of one of the STAT family 
molecules, involved in the signal transduction through GHR.  In particular, 
after GH stimulation no phosphorylation of STAT5 protein was observed in 
the cell lines of gc-negative patients in contrast to the control cells, in which a 
rapid activation of STAT5 occurred.  To define whether the blockage in GHR 
signaling was specific of STAT5 or involved other molecules as well, JAK2, 
STAT1, ERKs, and STAT3 phosphorylation were studied. No difference in 
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the phosphorylation events between the BCLs of patients and controls was 
appreciable and the expression of the molecules was comparable in control 
and patient cells. 
Moreover, as a strongly support of the interaction between GHR and gc, 
the reconstitution of X-SCID cells with the wild-type gc gene corrected the 
functional and biochemical abnormalities resulting in an appropriate nuclear 
translocation of STAT5, instead functional silencing of gc, obtained using a 
neutralizing Mab, causes a decrease in cellular response to GH. 
So, these data suggest that the gc is a necessary subunit of the GHR 
signaling complex in BCLs, where it is required for STAT5 phosphorylation 
and nuclear translocation, and not for the activation of other molecules of 
GHR signalling apparatus.  
These data have been published on The Journal of Immunology and 
reviewed on Current Signal Transduction Therapy, for the manuscripts see 
below. 
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Conclusive remarks 
 
The involvement of gc to the GHR apparatus confers some additional 
properties to this receptor in hemopoietic cells, but the specific functions 
remain to be elucidated.  Of note, in CD34+ progenitors (HPC), gc 
participates in hematopoietic cell differentiation by interacting with GM-
CSFRb. This interaction does not occur in normal NK cells or nonhemopoietic 
cells (31).  Hence, the complexity of receptor signaling relies not only on the 
possibility that individual receptors interact one with each other, but also on a 
differential array of distinct subunits that may represent a hallmark of that 
specific cell type.  
In conclusion, the evaluation of the existence of a previously 
unacknowledged link between individually well-studied elements, such as 
GHR and gc, confirm the cross-talk between receptor signaling systems as an 
emerging as well as important and exciting area of signaling research.  
In lymphocytes, several functions have been attributed to GH.  They 
include a mitogenic effect on T and B lymphocytes, help in cell development 
and lymphopoiesis of immune system (32) and potentiation of several 
functions, including NK activity.  GH also plays an anti-apoptotic effect on 
peripheral lymphocytes (33-34).   Thus, in principle it is conceivable to 
hypothesize a pharmacological intervention in tissue engineering and 
remodelling by interfering in such pathways.  The dissection of individual 
signaling pathways and the identification of the specific molecule implicated 
in that certain function remain the major goal of such novel therapeutic 
approaches.  The development of targeted therapeutics to activate growth 
inhibition (e.g. cancer) or stimulation (e.g. tissue engineering) represents the 
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major issue.  Progress in defining the pathogenic implications of GHR 
downstream molecules in cell growth might lead to the development of novel 
targeting strategies to fight those cancers that may be proven responsive.   
The participation of gc to several receptors implicated in the immune 
response would also suggest potential effects of GH in immune response, even 
though the precise role of the hormone is not completely defined.   
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§ 1.2                 The common g chain provides spontaneous and GH-      
dependent cell cycle progression, related to its cellular amount 
 
As already mentioned above, mutations of the IL2RG gene encoding the gc 
lead to the X-SCID (35-36).  The severity of this disease makes it a medical 
emergency, which without any treatment leads to death in the first months of 
life. Bone marrow transplantation represents in this context the conventional 
therapeutic strategy for this form of immunodeficiency.  This therapeutic 
approach confers to children affected by SCID at least a 70% chance of cure 
in the presence of a fully HLA-matched donor.  Unfortunately, a fully 
compatible donor is not always available, thus limiting the successful use of 
this therapy.  Moreover, the use of a not-fully HLA-matched donor increases 
the immunological complications such as Graft-versus-host-disease (GVHD) 
associated to a potential long-term decline in immune cell functions.  These 
difficulties encouraged gene therapy trials (37).  This strategy using ex-vivo 
retroviral vectors has been proven as a corrective therapeutic approach for X-
SCID in humans (38-43).  Immunological reconstitution has been documented 
in 17 out of 20 patients enrolled in two distinct clinical studies (37, 41).  
Unfortunately, 5 of these patients developed a lymphoproliferative disorder 
(44-46), not observed in gene therapy trials for SCID due to ADA deficiency 
(47).  This event was attributed to upregulated expression of the LMO2 
oncogene, as a consequence of insertional mutagenesis (48).  However, it was 
clearly documented only in 2 cases.  Even though the other patients may have 
the vector integration near LMO2 or other oncogenes (48), it is also 
conceivable that the transgene could have a role per se in cell cycle 
 34 
progression.  In keeping with this hypothesis, overexpression of gc transduced 
through a lentiviral vector into stem cells in a murine model of X-SCID led to 
T-cell lymphomas and thymic hyperplasia in a third of the cases.  Intriguingly, 
no common integration site was found between the mice, which developed T-
cell lymphomas (49).  In these mice, differently from humans treated with 
gene therapy for X-SCID, the expression levels of the protein was elevated 
thus implying that the amount of the protein may be crucial for the gc control 
of cell cycle (50).  These results suggest that insertional mutagenesis may not 
be the only cause of laeukemogenesis and that the expression level of IL2RG 
could influence the cell cycle progression directly or its effect being mediated 
by cytokines triggers.  
It has been documented that gc interleukin receptors activity enhance 
leukemogenesis (51).  In turn, this subunit activates several key signaling 
molecules, as JAK3, whose constitutive activation is frequently associated to 
autonomous cell growth and malignant transformation of lymphoid cells (52-
53).  Recently, as above mentioned, we demonstrated that gc subunit is also 
involved in GHR signaling in B lymphoblastoid cell lines (BCLs) (54).   
In this second part of the study, we show trough gc silencing experiments 
that the molecule is actively involved in a concentration dependent manner in 
self-sufficient growth and GH-induced cell cycle progression of BCLs, its 
activation being mediated by STAT5 phosphorylation and nuclear 
translocation. 
In particular, to define an intrinsic mitogenic property of gc dependent on 
the amount of the protein, we used in vitro cellular models containing 
different amounts of gc.  In particular, BCLs from normal subjects, cells 
transduced with lipid vector containing nontargeting short interfering RNA 
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(siRNA), BCLs transduced with siRNA to knockdown gc expression and 
BCLs from X-SCID patients were used.  Since self sufficiency in growth has 
been suggested as one of the six acquired capabilities of cancer phenotype 
(55), we examined the abilities of these previously mentioned BCLs to grow 
in serum-deficient conditions and showed that gc silencing inhibits self-
sufficient growth. Moreover, since JAK3 is essential for autonomous 
proliferation being physically linked to gc, we further investigated the role of 
gc in self-sufficient growth, evaluating JAK3 activation.  We found that the 
reduction of the protein down-regulates constitutively activated JAK3 in 
BCLs.  
It has been reported that GH enhances BCLs proliferation in vitro (56) and 
that gc is functionally linked to GHR (54).  Moreover, it has been described 
the association between lymphoproliferative events and supra-physiological 
doses of GH, both in mice and humans (57).  Since growth factors may 
participate in autocrine or paracrine loops that affect tumor cells growth or 
survival and autocrine production of GH is able to induce cellular 
transformation (58), we evaluated the response to GH stimulation of X-SCID 
BCLs, control cells and gc-silenced BCLs to assess whether gc amount could 
influence GH response.  We found that gc silencing also inhibits GH-induced 
cell proliferation.  In this context, since the activation of JAKs and STATs 
represents a prominent biochemical event during GH-dependent proliferation 
of lymphoid cell lines (29, 59-62) and STAT5 is considered a transforming 
agent in lymphoma and other cell types (63), we then evaluated whether gc-
silencing had effect on GH-induced STAT5 subcellular localization.  The 
result showed that the reduction of gc amount also inhibits STAT5 activation 
and the subsequent its nuclear translocation, that follows GHR perturbation. 
 36 
This study has been published on The Journal of Immunology, see the 
manuscript below.        
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Conclusive remarks 
 
These data add new evidence for a possible intrinsic mitogenic role of gc 
related to its cellular amount.  This biologic effect could be either direct, thus 
related to the molecule per se, or indirect and mediated by the participation to 
cytokine-receptors signaling. 
The intrinsic property of gc in cell cycle progression has been long 
debated.  In fact, although gene therapy trials have been proved as a beneficial 
alternative approach to cure X-SCID patients carrying mutations of gc, a 
malignant lymphoproliferation occurred in 5 out of 20 patients enrolled into 
the trials, alarming the scientific community (37).  To explain these adverse 
events, studies were conducted to define whether the retroviral insertional 
mutagenesis could have played a role.  In 2 cases an aberrant transcription and 
expression of LMO2 was clearly documented (48).  However, for the 
remaining patients there isn’t any evident demonstration of LMO2 alteration 
due to random insertions that could be causative in transformation.  An in vivo 
expansion of cell clones has also been documented in other gene therapy 
trials.  Two patients treated with gene therapy for X-linked chronic 
granulomatous disease developed myeloid proliferation.  Of note, in these 
cases cell clones didn’t exhibit any self-renewal capacity.  This would imply 
that there is no evidence of continued abnormal growth of clones containing 
insertionally activated growth-promoting genes (64).  Of note, development of 
leukemia, similar to other cancers, requires multiple genetic changes caused 
by a diverse group of genes that inhibit apoptosis and/or provide growth 
advantage to the leukemic cells (65).  Here, we demonstrate that gc exerts a 
role in cell cycle progression in a strictly concentration dependent manner.  
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We, also, found that the amount of constitutively activated JAK3 parallels the 
extent of gc expression.  This finding is intriguing, in that constitutively active 
or hyperactive JAK proteins have crucial roles in hematopoietic malignancies, 
by promoting oncogenic transformation and uncontrolled blood cell 
production (51).  In particular, JAK overexpression can be considered as one 
of the main biologic events leading to the constitutive activation of the JAK-
STAT pathway, that contributes to oncogenesis (53).  In lymphoid cells, the 
involvement of the JAK/STAT pathway in several cellular processes, such as 
proliferation and protection from apoptosis, has also been well documented 
(66-67).  Moreover, the role of JAK3 in cell destiny is emphasized by the 
finding that JAK3 mutations cause a SCID phenotype, thus implying its role 
in lymphoid development (68).  JAK3 has also the capacity to activate DNA 
synthesis and protooncogenes, such as c-myc and c-fos (69).   
In this study, we also observed that the participation of gc in GHR 
signaling apparatus and, in particular, in GH-induced STAT5 activation and 
nuclear translocation was also dependent on the extent of its molecular 
expression.  Thus, the concentration-dependent mitogenic effect of gc could 
be favoured by the participation of gc in GHR signaling.  Of note, it should be 
mentioned that experimental studies document a role for GH in the initiation 
and/or promotion of tumorigenesis, raising the possibility that patients treated 
with GH might be at increased risk of cancer (57).  Moreover, a putative role 
of GH as a cofactor in tumor growth is plausible, since several carcinomas 
express GHR (70).  In animal models, GH increase the incidence of leukemia 
and solid tumors, and in humans, at supraphysiological doses, it can promote 
lymphoproliferative events (71).   
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Our data would imply that the expression levels of gc in hematopoietic 
cells are crucial for the maintenance of cell growth control.   Whether our data 
may have direct implications in the understanding of the pathogenesis of the 
lymphoproliferative events occurring during gene therapy trials for X-SCID 
remains to be clarified.  Even though, under ordinary conditions, gc is 
expressed at a normal extent in cells, transduced with retroviral vectors 
containing wild-type gc, our data indicate that altering the expression levels of 
the protein could be important in modifying cell cycle control mechanisms.  
Our findings are in keeping with a recent study, which demonstrates that in X-
SCID murine model, T-cell lymphomas and thymic hyperplasia occurr in a 
third of the cases treated with lentiviral vectors containing wild-type gc (49).  
This event was independent from common integration sites and, thus, not 
attributable to insertional mutagenesis, but rather to an intrinsic oncogenic 
property of the transgene and, presumably, to the overexpression of the 
molecule (49).  Furthermore, by searching in Mouse Retroviral Tagged 
Cancer Gene Database, integration in Il2rg has been found in 2 cases of 
retrovirally induced leukemia (72).    
In conclusion, our data demonstrate a direct relationship between the 
amount of gc expression and its role in cell cycle progression.  Therefore, 
since results of gene therapy trials for X-SCID have been very promising, to 
achieve safer results, the modulation of the transgene expression could help 
reduce the risk of undesirable events.  
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CHAPTER 2 
The Nude/SCID phenotype 
 
In 1966, S.P. Flanagan identified a new mouse phenotype that spontaneously 
appeared in the Virus Laboratory of Ruchill Hospital, Glasgow, UK, 
characterized by loss of the hair.  This mouse showed an abnormal 
keratinization in hair fibers, with follicular infundibulum unable to enter the 
epidermis (1).  These affected mice also showed an inborn dysgenesis of the 
thymus resulting in a compromised immune system lacking T cells (1).  
 Subsequently, the molecular nature of the nude defect was characterized 
and attributed to a genetic alteration of the transcription factor Forkhead box 
(Fox) Foxn1 (also called Whn or Hfh11), mainly expressed in thymus and 
skin (2-4).  In addition, spontaneous mutations in the Foxn1 gene also occur in 
rats (4).  The rat ‘Whn’ locus is located on chromosome 10, and homozygous 
nude rats are phenotypically comparable to nude mice (5).  The analysis of the 
genomic sequence of the nude mouse revealed the presence of a single base-
pair deletion in exon 3, absent in the wildtype allele.  This deletion led to a 
frameshift that resulted in an aberrant protein prematurely terminating in exon 
6 and the loss of the postulated DNA-binding domain.   
 To verify that mutations of the identified gene were responsible for the 
nude phenotype Su et al. generated a Foxn1 allele, termed Foxn1-delta, that 
encoded a transcript lacking exon 3, resulting in a 154-amino acid deletion 
from the 285-residue N terminus of the protein (6).  Mice homozygous for this 
allele showed abnormal thymic architecture, lacking cortical and medullary 
domains.  In contrast to thymi from nude mice lacking Foxn1, thymi from 
mice homozygous for Foxn1-delta promoted T-cell development but with 
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specific defects at both the double-negative and double-positive stages.  Su et 
al. concluded that initiation and progression of thymic epithelial cell (TEC) 
differentiation were genetically separable functions of FOXN1 and that the N-
terminal domain is required for cross-talk-dependent TEC differentiation.  
 The mouse nude mutation led to an abnormal development of the skin and 
thymus (1, 7) and a severe alteration of the nails (8).  Later studies 
demonstrated that both defects, as lack of fur development and agenesis of the 
thymus, are pleiotropic effects of the same gene (9-10).  In particular, the skin 
of the nude mouse contains the same number of hair follicles as a wild type 
control, but these follicles result in an uncomplete hair, that could not enter 
skin surface (1, 8).  Flanagan analyzed carefully nude mouse skin and 
observed that at birth the hair follicles were normal, but by 6 days after birth 
the hair started to twist and coil, failing to penetrate the epidermis (1).  This 
hairless condition could be reverted by oral administration of cyclosporine A 
or recombinant keratinocyte growth factor (KGF or FGF-7), that influence the 
number of hair follicles or the cyclic hair growth (11).  Furthermore, the nude 
mouse epidermis shows failure in differentiation and a reduced number of 
tonofilaments are observed in spinous, granular and basal layers (8).  The 
nude Foxn1 gene doesn’t affect the growth of hair follicles, but the epidermal 
differentiation process, regulating the balance between proliferation and 
differentiation of keratinocytes in the hair follicle (12-13).  
 In addition to these cutaneous abnormalities, nude animals develop an 
abnormal thymus, resulting in a severe T-cell deficiency and an overall 
severely impaired immune system.  In fact, thymus morphogenesis is stopped 
at the first stages with no subcapsular, cortical, and medullary regions 
formation, which characterizes a normal mature organ (10).  In addition, the 
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observation that thymus restoration doesn’t lead to hair growth demonstrated 
that the lack of the hair and the athymia were not related one with each other 
(9-10). 
 Furthermore, nude phenotype is characterized by nail malformations and 
poor fertility.  The first condition is, probably, due to an abnormal production 
of filaggrin protein in nail matrix and nail plate, subsequent to a loss of 
Keratin 1 protein.  Instead, the second condition may be the result of changes 
in hormonal status, as demonstrated by altered serum levels of estradiol, 
progesterone and thyroxine (8).  
 In nude mice the thymic agenesis is congenital and it closely resembles 
thymic agenesis of newborns affected with DiGeorge syndrome (11). 
DiGeorge syndrome occurs spontaneously and children with this syndrome 
are characterized by thymic hypoplasia or aplasia.  Unlike the association of 
hairlessness in the nude mouse, DiGeorge syndrome was found to be often 
associated to neonatal tetany and major anomalies of great vessels. These 
latter defects, due to malformation of the parathyroid and heart, derived from 
a major embryologic defect in the third and fourth pharyngeal pouch from 
which the thymus primordium emerged.  Children with the DiGeorge 
syndrome also manifest lymphopenia, reduced number of T cells, poorly 
responsive to common mitogens (14).  These similarities led to an erroneous 
interpretation of DiGeorge syndrome as the human counterpart of nude mouse 
phenotype for many years until the first description of the human equivalent 
of the Nude/SCID phenotype, which represents the real athymic human 
model. 
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§ 2.1             Novel immunodeficiencies: the model of the human 
Nude/SCID phenotype 
 
More than 30 years from the original description of spontaneous murine 
disease, the first human equivalent of the Nude/SCID phenotype was 
described in 1996.  The identification of the human counterpart of nude mouse 
phenotype began with identification of two sisters, whose clinical phenotype 
was characterized by congenital alopecia, eyebrows, eyelashes, nail dystrophy 
and a several T-cell immunodeficiencies, inherited as an autosomal-recessive 
disorder (15).  The T-cell defect was characterized by severe functional 
impairment, as shown by the lack of proliferative response.  The functional 
abnormality occurred in spite of the presence of a few phenotypically mature 
T cells, thus suggesting the qualitative nature of the defect (15).  Since 
alopecia and nail dystrophy are also found in other syndromes, such as 
dyskeratosis congenita (DC) (16-17), other signs of this disease were 
investigated.  Differently from DC, major signs, such as abnormal 
pigmentation of the skin and mucosal leucoplakia, were lacking in 
Nude/SCID and the immunological abnormalities were different from those 
reported in patients with DC in both severity of clinical course and type of 
alterations (18-19).  Moreover, both patients showed alopecia at birth and in 
one sib it still persisted after bone marrow transplantation, thus ruling out that 
it was secondary to acquired skin damage.  This finding suggested that the 
alopecia in this patient was primitive in nature (20).  Furthermore, these 
features were similar to those reported in athymic mice, that completely lack 
body hair and in which restoration of a thymus did not lead to hair growth 
(21).  Taken together, these observations suggested an association between 
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alopecia and the immunodeficiency reported in the 2 sisters, linked to a single 
gene defect (15).   
 In humans, “FOXN1” is located on chromosome 17 (22) and it encodes a 
transcription factor mainly expressed in the epithelial cells of the skin and 
thymus, maintaining the balance between growth and differentiation.  Later, a 
molecular analysis in these patients was performed and revealed the presence 
of a C-to-T shift at 792 nucleotide position in the sequence of the FOXN1 
cDNA that leads to a nonsense mutation R255X in exon 5, with a complete 
absence of a functional protein (22) similar to the previously described rat and 
mouse Foxn1 mutations (23-25).   
 The FOX gene family comprises a diverse group of ‘winged helix’ 
transcription factors that are involved in development, metabolism, cancer and 
aging. These transcription factors share the common property of being 
developmentally regulated and of directing tissue specific transcription and 
cell fate decisions (26).  They were first recognized in Drosophila, but later 
they were also identified in other organisms, from yeasts to humans. The term 
FOX is now used to refer to all chordate forkhead transcription factors. A 
phylogenetic analysis led to classify all known FOX proteins in at least 15 
subfamilies (named from A to Q) (27) on the basis of their structure; in each 
subfamily (or class), an individual gene is identified by a number. The crystal 
structure of the forkhead DNA binding domain is a ‘winged helix’ motif, 
consisting of three a helices flanked by two ‘wings’ of b strands and loops 
(28). The structure and the amino acids sequence are highly conserved within 
species and family members.  The functional effect of all FOX proteins can be 
either the activation (transactivation) or the inhibition of gene transcription33 
in a wide range of context. Fox gene mutations can be associated with diverse 
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phenotypes as cranio‑pharyngeal developmental defect (FOXE1), speech and 
language abnormalities (Foxp2) and hearing loss (Foxj1) (29).  Moreover, 
most of these winged helix proteins play crucial roles in several aspects of 
immune regulation. In particular, genetic alterations of at least four FOX 
family members, FOXP3, FOXJ1, members of the FOXO subfamily and 
FOXN1, result in paradigmatic immune disorders and well defined novel 
clinical entities (30). 
 FOXP3 (scurfin, sf, JM2) is the most studied forkhead family member in 
immunology, because of its role in the pathogenesis of autoimmunity 
associated with immunological functional disorders (31-33).  FOXP3 was 
found to be expressed in CD4+ CD25+ regulatory T ‑ cells (Treg), that 
represent a subset of CD4+ T‑cells bearing high levels of CD25 (the IL‑2 
receptor a‑chain), whose role is to maintain self‑tolerance by downregulating 
the reactivity of conventional CD25– CD4+ helper T‑cells (32, 34).  Foxp3 is 
also expressed in lymphoid organs, such as spleen and thymus, where it plays 
an essential role during development, allowing the differentiation of the Treg 
population. The study of scurfy mice (mice with X‑linked recessive mutation 
in Foxp3) revealed an overproliferation of activated CD4+ T‑cells, resulting 
in dysregulation of lymphocyte activity (35-36).  The lack of DNA binding 
domain of the protein leads to death of hemizygous males at 16-25 days after 
birth (35-36) and in the surviving mice in a great exacerbation of the 
autoimmune phenotype (37). 
 The corresponding human disorder is represented by 
Immunodysregulation Polyendocrinopathy Enteropathy X-linked syndrome 
(IPEX; also known as X‑ linked autoimmunity and allergic dysregulation 
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syndrome, XLAAD). This fatal recessive disorder is due to truncated protein 
or inhibition of DNA binding domain. It develops in early childhood and is 
associated with protracted diarrhoea, thyroiditis, dermatitis, allergic 
manifestations, insulin ‑ dependent ‑ type 1 diabetes and anaemia, besides 
massive T‑cell infiltration into the skin and gastrointestinal tract and high 
serum levels of autoantibodies, as a sign of autoreaction.  Recent studies have 
shown that the expression of FOXP3 and the subsequent conversion of human 
and mouse peripheral naïve T‑cells in Treg is induced by TGF‑β (38-39).  
Most probably, this event is mediated by activation of Small Mothers Against 
Decapentaplegic (SMAD) transcription factors. Generally, the inhibition of 
TGF‑β‑mediated signaling involves SMAD7 in an autoregulatory loop, but it 
was also shown that FOXP3 can inhibit it, as well.  The induction of FOXP3 
expression by Treg results in a prolonged TGF‑β‑mediated signaling perhaps 
allowing the stabilization or expansion of the Treg pool (30). 
 FOXOs are the mammalian homologues of the Caenorhabditis elegans 
dauer formation mutant 16 (DAF‑16) and, in this organism, they seem to be 
involved in longevity regulation.  FOXO1 (FKHR, forkhead in 
rhabdomyosarcoma), FOXO3A (FKHRL1, FKHR‑ like 1), FOXO4 (AFX, 
mixed lineage ‑ leukemia (trithorax homolog) translocated to 7 homolog, 
Mllt7) and FOXO644 are the most studied members of this family for their 
implication in the regulation of apoptosis, cell cycle, metabolism and 
resistance to oxidative stress (40-42).  Gene targeting experiments in mice 
have demonstrated that FOXO1 regulates insulin sensitivity (43-44), 
adipocyte differentiation (44) and angiogenesis (45), while FOXO3A 
regulates ovarian development and fertility (46-48) and FOXO4 appears to be 
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largely dispensable for gross organismal homeostasis (48).  FOXO proteins 
are ubiquitously expressed, even if there is a tissue specific expression for the 
diverse isoforms. While FOXO1 is ubiquitous, FOXO3A is expressed in 
lymphocytes and it appears the dominant isoform of the mammalian family. 
Cellular stimulation by mitogens or cellular stress, leads to activation of 
several intracellular kinases such as phosphatidyl inositol 3 kinase (PI3K), 
serum/glucocorticoid‑regulated kinase (SGK) and protein kinase B (PKB, 
Akt), resulting in the phosphorylation of the FOXOs.  This makes FOXO 
unable to bind DNA and renders it susceptible to nuclear export and/or 
proteasome mediated degradation (IkB kinase (IKK)) thereby preventing 
FOXO‑mediated transcription (49-50).  In resting cells, unphosphorylated 
forms of the FOXOs are localized in the nucleus, where they are 
transcriptionally active and regulate several biologic processes, including 
proliferation, apoptosis and response to cellular stress.  To date, there is no 
evidence that an altered FOXO activity is associated with a human 
immunological disease. However, in mice a significant diminished FOXO 
activity in T‑ cells is associated with autoimmune lupus syndrome, thus 
leading to hypothesize a possible relationship between the FOXO genes and 
inflammation in humans (50).  Differently, FOXO gene dysregulation has 
been well documented in human cancer. 
 The FOXJ1 (hepatocyte nuclear factor/forkhead homolog‑4, HNF‑4, 
FKHL‑13) transcription factor plays an important role in the development of 
ciliated epithelia (51).  Thus, FOXJ1 is expressed in all structures containing 
ciliated cells, such as the lungs, spermatids, oviducts and choroid plexus (52).  
The loss of FOXJ1 results in lethality in uterus or soon after birth as 
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demonstrated by observations of Foxj1–/– mice that die during embryonic 
development (53-54).  In fact, Foxj1‑deficient mice are characterized by 
absence of cilia and, subsequently, suffer from significant developmental 
abnormalities including heterotaxy and hydrocephalus (30).  Besides its role 
in the differentiation of ciliated cells, recently a new role for FOXJ1 has been 
discovered in the differentiation of other cell types. It was observed that Foxj1 
is downregulated in lymphocytes isolated from mice affected with systemic 
lupus erythematosus (SLE); this evidence suggests that FOXJ1 might prevent 
autoimmune reactions (55).  FOXJ1 is expressed in naïve T‑cells and its 
downregulation occurs after IL‑2 and/or TCR stimulation (55).  FOXJ1, 
similarly to FOXO3A, is required in vivo to modulate NF‑kB activity, 
upregulating IkBβ and maintains T ‑ cell tolerance, but unlike FOXO3A 
deficiency, FOXJ1 deficiency is much more severe, affecting a different 
spectrum of organs and Th1 cytokine production. Thus, these two forkhead 
members play either overlapping or clearly distinct roles in helper T‑cells, 
even though the intimate mechanisms remain to be elucidated (56). 
 Foxn1, a highly conserved transcription factor, has been previously 
extensively mentioned. It exerts its function after activation through 
phosphorylation that promotes its nuclear translocation (57-59).  Into the 
nuclei it interacts with DNA as a monomer through its forkhead box, but the 
target genes and the specific biochemical mechanism of interaction with the 
promoter regions remain to be elucidated (28, 60).  FOXN1 expression is 
strongly regulated by wingless (Wnt) proteins (61) and bone morphogenetic 
proteins (BMPs) (62) in both autocrine and paracrine fashions (56) and its 
expression is restricted to epithelial cells in the skin and in the thymus. There 
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are no data available on FOXN1 mRNA expression in liver, spleen, testis, 
lung, heart and brain, but murine choroid plexus (63).  During embryogenesis, 
FOXN1 is expressed in several mesenchymal and epithelial cells, including 
those of the liver, lung, intestine, kidney and urinary tract. In adult life, its 
expression is limited to epithelial cells of the intestine, spermatocytes of the 
testis and thymus (64).  In particular, on the basis of the observation that nude 
mice keratinocytes do not differentiate in a normal fashion, FOXN1 could be 
considered as a key regulator of the balance between keratinocytes growth and 
differentiation. It suppresses the involucrin and locrin expression, both 
components of the cornified envelope and the profilaggrin, involved in the 
aggregation of the intermediate filaments. 
 Other factors have been identified as Foxn1 target. In fact, recent studies 
have shown that Foxn1 is linked to Akt (PKB) expression (65), thus giving a 
possible explanation of FOXN1 involvement in epidermal layer regulation. 
FOXN1 also controls follicular formation, influencing the expression of two 
hair keratins, mHa3 and mHb5 (3). 
 All these findings associated with an extensive review of the literature 
have been the bases for a Book Chapter published by Landes Bioscience, that 
has received a great echo in the editorial and scientific communities and so it 
has been co-published by Springer and cited in Pubmed, for the chapter see 
below. 
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Conclusive remarks 
 
The cited work contains recent information that came out from the original 
description of Nude/SCID phenotype. For the first time, only recently, a 
careful description of clinical manifestations associated with an alteration of 
the FOXN1 gene has been provided, thus leading to identify the human 
equivalent of the well studied spontaneous murine Nude/SCID 
immunodeficiency.  In this context, alterations of FOXN1 and of other 
members of FOX subfamilies are now emerging as intriguing causes of 
immunological disorders mainly characterized by abnormal T ‑ cell 
development or abnormal T ‑ cell regulatory homeostasis.  Eventually, it 
should be underlined that the Nude/SCID phenotype is the only form of SCID 
associated with an alteration of a gene that is not expressed in the 
hematopoietic cell. 
 Novel knowledge in this field would be very helpful in the comprehension 
of the intimate mechanisms underlying T‑cell ontogeny process in humans 
and in discovering novel clinical entities related to abnormalities of the 
process. 
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§ 2.2          FOXN1 homozygous mutation associated with anencephaly 
and severe neural tube defect in human athymic Nude/SCID fetus 
 
In the village where the first Nude/SCID patients were identified a genetic 
counselling was offered to couples at risk.  The prenatal diagnosis by direct 
genetic analysis of FOXN1 led to identify an affected female fetus during the 
first trimester of pregnancy, thus indicating the importance of this effort.  The 
fetus was homozygous for R255X mutation and the autoptical examination 
revealed the absence of the thymus and a grossly abnormal skin which was 
tighter than usual and which showed basal hyperplasia and dysmaturity, 
suggestive of an impaired differentiation program.  These signs confirmed that 
FOXN1 is involved in thymic development and skin differentiation in 
humans.  Of note, the fetus also showed multiple-site neural tube defects, 
including anencephaly and spina bifida that could explain the high rate of 
mortality in uterus observed in the described population.  During our study, 
we also showed that while there have been no prior studies of FOXN1 activity 
in the nervous system, we observed that the mouse Foxn1 gene is expressed in 
epithelial cells of the developing choroid plexus, a structure filling the lateral, 
third, and fourth ventricles of the embryonic brain.   
 Another aspect that led to consider the Nude/SCID mutation and 
anencephaly causally related is the fact that the other forms of SCID become 
clinically evident in post-natal life, when the protection of the newborn by the 
mother immune system declines.   
 Moreover, the expression of Foxn1 in the embryonic choroid plexus is 
consistent with a possible role for Foxn1 in the development of the central 
nervous system. The expression in choroid plexus is intriguing, suggesting 
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that disturbances in cerebrospinal fluid (CSF) secretion may play a role in the 
pathogenesis of defects at both ends of the neural tube. 
 After this first observation, we identified a second fetus belonging to the 
same family that carried the R255X homozygous mutation in FOXN1.  This 
fetus was examined for the presence of central nervous system (CNS) 
developmental anomalies.  Prenatal diagnosis, performed by villocentesis at 
11 weeks of gestation, led to a diagnosis of Nude/SCID syndrome.  At 16 
weeks of gestation, the abdominal sonography of the Nude/SCID fetus 
revealed a morphologically normal brain, but with absence of cavum septum 
pellucidum (CSP), in that only medial wall of the frontal horn was observed.  
At this age, CSP is a fluid-filled cavity situated between the membranes which 
form the septum pellucidum and bounded superiorly and anteriorly by corpus 
callosum and inferiorly by the fornix and is considered a marker of a normal 
anatomy (66).  However, this structure is seen in the 40% of cases at 15 
weeks, 82% at 16-17 weeks, and 100% after the 18th week of gestation (66).  
After parents decision, the termination of pregnancy was performed at 18th 
week and the fetus was further examined postmortem after obtaining informed 
consent.  At autopsy, the brain weight was 35 g and a first gross examination 
revealed an enlargement of the interhemispheric fissure.  A magnetic 
resonance imaging (MRI) of the extracted brain showed the integrity of major 
structures, but some mechanical damages due to extraction procedures.  
Cerebellum, brainstem, midbrain and thalami were normally formed and 
ganglionic eminence could be clearly defined.  Convexity sulci and lamination 
of brain parenchyma were normal for gestational age (67-68).  On the 
contrary, corpus callosum could not be identified in any section.  Furthermore, 
in keeping with this, subsequent autopsy failed to reveal any macroscopic 
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abnormality of brain structures, but the abnormality in the development of 
corpus callosum. 
 The first of these 2 observations has been published on Clinical Genetics, 
while the other one has been submitted to the Journal of Neurology and it is 
under review, for the manuscripts see below.      
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Conclusive remarks 
 
The reported observations open a new window in the comprehension of the 
role of FOXN1 in the development of different tissues, such as CNS, 
confirming former observations related to other FOX family members (29).  
Although our reports revealed 2 distinct CNS phenotypes associated to the 
same FOXN1 gene mutation (R255X), they would suggest that FOXN1 
alterations could play a role as cofactor in CNS development in a similar 
fashion to other FOX family members, such as FoxP1, that helps Hox proteins 
to regulate the genes that control motor-neuron diversification (69-70).   
 It should be noted that mice defective in HNF-3b through gene targeting 
technology lack a notochord, which results in severe defects of neural tube 
organization (71).  In addition, other members of the FOX family, such as 
Foxj1, have already been identified as important molecules for development 
of choroid plexus epithelium, thus implying a potential role for these proteins 
in the nervous system development. It has been recently observed that in 
Xenopus laevis, another FOXN factor, FOXN4, is expressed in brain and 
retina at the earliest stages of maturation.  FOXN4 is also expressed in the 
pallium, optic tectum, isthmus, reticular formation, and in cells lining the 
ventricle of the tadpole brain (72). In humans, alterations in the FOXP2 gene 
are associated with neurodevelopmental disorders, suggesting that the 
molecule has a key role in neural functioning (73).  Thus, different from 
Foxp2 that is expressed later as a regulator gene, Foxn1 seems to be 
implicated as an organizer in neurulation.  Moreover, the zebrafish orthologue 
of the mouse nude gene Foxn1 is observed in the developing eye and several 
other brain structures (74).  Recently, it has also been shown that Foxn1 is 
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required to maintain the expression in the hair follicle matrix of Notch1 (75), 
whose signaling is known to regulate cell fate specification and pattern 
formation in the developing nervous system (76).   
 Nevertheless, the precise role of the FOXN1 transcription factor in CNS 
development remains to be fully clarified.  Our cases should encourage 
physicians and pathologists to search for FOXN1 alterations in congenital 
brain development abnormalities. 
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CHAPTER 3 
The Ataxia Telangiectasia 
 
Among those PIDs whose causing genes are not selectively expressed in the 
hematopoietic compartment there is Ataxia-telangiectasia (A-T), a rare 
autosomal recessive disorder, characterized by progressive neurological 
dysfunction, especially affecting the cerebellum, oculo cutaneous 
telangiectasia, high incidence of neoplasms and hypersensitivity to ionizing 
radiations (1-2).  
 Immunodeficiency is present in 60-80% of individuals with A-T, it is 
variable and do not correlate well with the frequency, severity or spectrum of 
infections (3).  The immunodeficiency is progressive and the most consistent 
immunodeficiency reported is poor antibody response to pneumococcal 
polysaccharide vaccines (3).  Moreover, serum concentration of the 
immunoglobulins IgA, IgE and IgG2 may be reduced.  Approximately 30% of 
individuals with A-T who have immunodeficiency have T-cell deficiencies.  
At autopsy, virtually all individuals have a small embryonic-like thymus.  
Unlike most immunodeficiency disorders, the spectrum of infection in 
individuals with A-T does not comprise opportunistic infections.  Some 
individuals develop chronic bronchiectasis and the frequency and severity of 
infections correlates more with general nutritional status than with the 
immune status.  Individuals with frequent and severe infections appear to 
benefit from intravenous immunoglobulin (IVIG) replacement therapy (3); 
however, longevity has increased substantially even in individuals not 
receiving IVIG.   
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 The disease is associated with mutations in the ataxia telangiectasia 
mutated (ATM) gene encoding for a 370 kDa serine/threonine kinase, that 
shares sequence similarities with the catalytic subunit of phosphatidyl-
inositol-3-kinase (4). Most of its substrates appear to be involved in cell cycle 
checkpoints and DNA double-strand break (DSB) response (5). Thus, the 
disease is considered the prototype of the DNA-repair defect syndromes (6).   
 The clinical course of the disease is severe, and the median survival of A-
T patients is actually 19–25 years with a wide range (7).  A variable immune 
defect has been long recognized in patients with A-T (8). Immunological 
abnormalities mainly include impaired antibody responses, T-cell 
lymphopenia, primarily affecting CD4+ lymphocytes, and impaired 
proliferative response to mitogens and antigens (3). However, severe 
infections are uncommon in A-T (3). On the contrary, clinical signs related to 
the progressive neurodegeneration are overwhelming and dramatically affect 
the quality of life.  Purkinje cells are thought to be selectively depleted, then 
resulting in the progressive cerebellar atrophy of the cortex associated with 
significant thinning of the molecular layer, as revealed by autopsy and biopsy 
studies (9-10).  Unfortunately, currently there is no effective treatment for A-
T, but supportive care of neurological symptoms, as physical, occupational 
and speech/swallowing neurorehabilitation. Eventually, the progressive 
neurodegeneration and pneumonia are a frequent cause of death in patients 
with A-T. 
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§ 3.1          Effects of steroid treatment in patients affected with Ataxia 
telangiectasia 
 
A recent clinical observation reported on a dramatic improvement of 
neurological symptoms following a short course of oral betamethasone in a 
child affected with A-T (11). Due to the importance of the topic, this study 
aimed to extend such an observation to additional A-T patients referred to a 
single Immunodeficiency Center. 
 In this part of the study, we reported on the amelioration of neurological 
signs, assessed by Scale for the Assessment and Rating of Ataxia (SARA), 
during short-term treatment with oral betamethasone.  Of note, this effect was 
observed not only in very young A-T patients, but also in older ones. The 
clinical response was observed as soon as 48 h following the beginning of the 
therapy and was transient, in that it disappeared soon after therapy 
withdrawal.  The highest clinical improvement was on speech disturbance, 
stance, and finger chase items. 
 This study has been published on The European Journal of Neurology, for 
the manuscript see below.  
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Conclusive remarks 
 
The clinical phenotype of A-T is quite heterogeneous with a surprising, and 
still unexplained, different impact of the pathogenic mechanism on the 
severity of immunological and neurological signs.  Differently from 
lymphocytes, whose turn-over is continuous and characterized by the release 
into the peripheral stream of fully differentiated mature cells from bone 
marrow, the placement of Purkinje neurons occurs relatively early in human 
development (1). This would suggest that early alterations in cell development 
during mid-gestation underlie the A-T-related ataxia (12-13).  Thus far, the 
worst aspect in the follow-up of A-T patients is the lack of an effective 
specific treatment for the neurological impairment.  This observation confirms 
what recently reported on a single patient, and clearly indicates that for many 
years from the disease onset, neurological symptoms in A-T patients are 
susceptible of beneficial pharmacological intervention.  However, due to the 
number of well-known adverse effects of corticosteroids, this therapy should 
be undertaken only after a careful consideration of the individual case.  Most 
importantly, the rescue of the neurological function, at some extent, suggests 
that cell loss is an ultimate feature in A-T and the biochemical alterations, 
presumably reversible, proceed for a long time cerebellar atrophy.  Further 
studies on the implicated mechanisms may open an important window on 
novel therapeutic agents capable of controlling neurological symptoms in A-
T. 
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§ 3.2         In Ataxia Telangiectasia patients betamethasone response is 
inversely correlated to cerebellar atrophy and directly to 
antioxidative capacity 
 
As above mentioned, neurological symptoms in A-T patients are susceptible 
of beneficial pharmacological intervention obtained trough betamethasone 
therapy.  Conversely, the intimate molecular mechanism by which 
betamethasone led to this effect remains unclear, thus it is not possible to give 
a definitive explanation of this finding.  However, the normal function of 
ATM in the nervous system nor the biological basis of the degeneration in A-
T is known (12).  Although ATM seems to be neuroprotective in the tissue 
undergoing oxidative stress and apoptosis, the intimate molecular mechanism 
of its property is still uncertain (14).  As the effect of betamethasone was 
transient in nature, it should be argued that the intimate mechanism of this 
pharmacological action regards some still unidentified steroid-dependent 
biochemical event.  This is not surprising, because a permanent reversion of 
the molecular alteration is not expected, and the drug presumably acts on the 
damage derived from ATM dysfunction.   
 ATM also plays a role in the signal transduction network that modulates 
cell cycle checkpoints, genetic recombination, apoptosis, and other cellular 
responses to DNA damage (6, 15-16).  Recently, increasing attention is being 
paid to the role of oxidative stress in the pathophysiology of A-T and other 
inherited ataxias (6).  In fact, while tumorigenesis in A-T seems to be linked 
to genetic instability, oxidative stress seems to play a major role in 
neuropathology (12, 17-18).  The cerebellum has been proven to be a target 
for oxygen damage resulting in neurodegeneration.  In Atm-/- mice, enhanced 
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oxidative stress reduces life span and cells are more sensitive to radiations, 
thus suggesting that free radicals are important cofactors in the expression of a 
few A-T clinical features (19).  In keeping with this observation, 
administration of an antioxidant clearly prevented Purkinje cell death in Atm-
deficient mice (9, 14).  Taken together, these data provide evidence that 
oxidative stress contributes to the clinical phenotype of the disease (20).  It is, 
therefore, conceivable to hypothesize that the reported observation might be 
linked to a biochemical alteration of such a balance. 
 With this regard, in the second phase of this study we evaluate whether the 
beneficial effect of betamethasone therapy could be mediated by interference 
in reactive oxygen species (ROS) generation/neutralization process.  Thus, we 
measured in this small cohort of A-T patients direct markers of ROS 
production, during a short-term steroid treatment. 
 Of note, ATM protein, after its autophosphorylation, activates multiple 
substrates involved in cell cycle regulation, such as p53 and, eventually, leads, 
cooperating with other DNA repairing factors, to cell cycle arrest.  ATM is 
also involved in sensing and modulating intracellular redox status, even 
though it is not clear whether ATM itself is directly involved in ROS 
production (16, 21).  However, ATM deficiency causes oxidative damage to 
proteins and lipids in brain, testes and thymus.  Furthermore, Atm-deficient 
mice exhibit genomic instability and hypersensitivity to ionizing radiation and 
other treatments that generate ROS (22).    
 In keeping with this, in Atm-deficient mice the overexpression of 
superoxide dismutase 1 (SOD), an enzyme involved in hydrogen peroxide 
production, exacerbated certain features of the A-T phenotype (23).  These 
observations point to additional roles for ATM in cellular metabolism other 
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than its direct role in the response to DSBs induction, such as its involvement 
in ROS balance. 
 Cells have developed a wide array of protective mechanisms against ROS, 
including small reducing molecules, antioxidative enzymes and damage/repair 
systems (24).  One of the small reducing molecules is glutathione (GS), which 
appears in the cells in both its oxidized and reduced (GSH) forms.  It works in 
detoxifying specific ROS by itself or in combination with other enzymes, such 
as SOD, which converts superoxide radicals into H2O2 and O2, catalase, 
glutathione peroxidase (PHGPx) and glutathione-S-transferases.  Oxidants 
overproduction and/or dysfunction of endogenous antioxidant defenses result 
in oxidative stress induced injury with damage to all the major classes of 
biological macromolecules, such as nucleic acids, proteins, lipids and 
carbohydrates.  The CNS is particularly vulnerable to oxidative stress due to 
its high rate of metabolism and to the disproportionately low levels of its 
oxidative defense mechanisms (25).  The increased and unopposed ROS 
production can lead to neurotoxicity resulting in neural damage and eventually 
in cell death.  
 Within the observation of the neurological amelioration during steroid 
treatment in A-T patients, we found that this improvement was inversely 
correlated with the age and severity of cerebellar atrophy and that the highest 
basal GSH values were present in PBMC from those patients who better 
responded to the betamethasone therapy.  Furthermore, it is interesting to note 
that the behaviour of ROS levels in the patient, who better responded to the 
treatment, correlated with the clinical improvement.  In particular, ROS levels 
decreased during the phase of the improvement and returned to normal seven 
days off the therapy, paralleling the clinical worsening.  During this study, we 
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analyzed also lipid peroxidation and found that this phenomenon occurred 
only in the patient who did not exhibit any clinical improvement during the 
therapy and, importantly, that it was associated with the most severe 
cerebellar atrophy.  These findings suggested that the antioxidative protective 
GSH system plays a role in the protection from the cerebellar atrophy and 
may be implicated in the improvement of cerebellar functions during short-
term betamethasone therapy. 
 This work has been published on The European Journal of Neurology, for 
the manuscript see the attached file below.        
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Conclusive remarks 
 
Even though A-T is non-curable we had previously demonstrated an 
improvement of the cerebellar functions in 6 A-T patients after a short-term 
betamethasone therapy (0.1 mg/kg/day for 10 days) (26).  Although the 
clinical response to betamethasone was evident, there was no evidence 
indicating the intimate mechanism of action of this drug in A-T.  In this 
second study, on the basis of our finding, we concluded that betamethasone 
response in A-T patients is inversely correlated to cerebellar atrophy and 
directly to antioxidative capacity.  The importance of this study relies 
principally on the severity of the neurological signs.  In fact, this childhood 
disease is characterized by progressive impairment of gait and speech, 
oculomotor apraxia (inability to move the eyes from one object to another), 
oculocutaneous telangiectasia (dilated blood vessels), cerebellar atrophy, 
sterility and radiosensitivity (12). Approximately, 10%–15% of A-T patients 
develop cancer, most frequently acute lymphocytic leukemia and lymphoma.  
The prognosis for survival is poor, and individuals with this disease usually 
die in their teens.  The earliest clinical manifestation of A-T is ataxia (2).  By 
approximately 4 years, deterioration of gross and fine motor skills occurs; eye 
movements are characterized by a series of small jumps rather than in a single 
smooth motion (oculomotor apraxia); choreiform movements of the hands and 
feet are observed, difficulty with chewing and swallowing occur and drooling 
is common.  A-T is primarily a syndrome of progressive cerebellar ataxia but 
more diffuse changes to the CNS are also evident.  Cerebellar degeneration in 
A-T manifests as dystrophic changes involving the dendrites and axons of 
Purkinje cells and ectopic Purkinje cells are evident.  Of all the features of A-
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T the progressive cerebellar neurodegeneration is the most debilitating.  By 
the end of the first decade ataxia has progressed to the extent that the child is 
confined to a wheelchair and may have poor control of head and torso leading 
eventually to spinal muscular atrophy.  Thus, any effective treatment for A-T 
would ideally involve prevention or at least slowing of the progressive 
neurodegeneration.  As mentioned above, at present there is no therapy 
available to cure or prevent the progress of A-T, but it is possible to alleviate 
some of the symptoms associated with immunodeficiency and deficient lung 
function but neither the cancer predisposition nor the progressive 
neurodegeneration can be prevented.  In conclusion, this multisystem disease 
requires intervention to: (i) halt progressive neurodegenerative changes; (ii) 
reduce the risk or treatment of tumours; (iii) correct immunodeficiency; (iv) 
alleviate bronchial complications.  There is no cure for the progressive 
neurodegeneration with conventional therapies but some promise exists.  Most 
importantly, the rescue of the neurological function, at some extent, suggests 
that cell loss is an ultimate feature in A-T and those biochemical alterations, 
presumably reversible, proceed for a long time cerebellar atrophy.   
 This study on the implicated mechanisms may open an important window 
on novel therapeutic agents capable of controlling neurological symptoms in 
A-T. 
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CHAPTER 4 
The T-cell ontogeny: from positive to negative selection 
 
A normal T-cell ontogeny and the generation of a heterogeneous 
peripheral T-cell pool are essential for a normal immune response.  To 
date, the “primary” organ for the differentiation and selection of T cells is 
represented by the thymus that, providing a complexity of specialized cells 
as epithelial and dendritic cells, macrophages and fibroblasts of the stroma 
(1), influences each stage of T-cell precursor maturation program (2). 
One of the important regulators of thymic epithelium, whose integrity 
is crucial for T-cell maturation, is represented by the product of the nude 
gene locus, FOXN1, above extensively described. 
During the maturational process, first HPCs emerge from bone marrow 
and reach the thymus where a complex series of maturational proceedings 
take place, an event known as positive selection (3). 
Within the thymus, recently formed T cells also undergo negative 
selection, or central tolerance, whose hallmark is the clonal deletion of 
self-reactive T clones, being this process efficiently mediated by bone-
marrow derived dendritic cells (DCs).  In the thymus, the negative 
selections distinguishes T cells with low or high affinity for self-antigens, 
whose transcription is induced by the autoimmune regulator (AIRE) gene 
product, and self-MHC and eliminate those clones with more affinity for 
self.  Really, some autoreactive clones could escape thymic control; these 
cells are however controlled in the periphery.  The establishment of the 
peripheral tolerance is attributable to the induction of functional anergy, 
deletion by apoptosis, and the suppressive actions of regulatory T 
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lymphocytes (Treg).  Each of these pathways is essential for maintaining 
self-tolerance.    
Mutations in the AIRE gene lead to defective clonal deletion and to the 
multi-organ syndrome known as autoimmune – polyendocrinopathy – 
candidiasis – ectodermal distrophy syndrome (APECED).   
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§ 4.1                      FOXN1 mutation abrogates pre-natal  
              T-cell development in humans 
 
The genetic study of human SCID has unravelled in the last 2 decades 
important issues concerning the rules that govern lymphocyte 
development and function (4).  The thymus has been long and 
unanimously considered the unique primary lymphoid organ where 
ontogeny of T cells, which are the essence of the cellular immune system, 
occurs (5).  However, although an extensive knowledge exists about 
thymus role in T-cell development, a fully comprehension of this 
mechanism remains unexplained.  In particular, important issues remain 
unclear about the involvement of different non-lymphoid tissues such as 
skin, gut, or liver in T-cell ontogeny.  A second thymus-like organ able to 
support T-cell full maturation and to reconstitute T-cell compartment in 
athymic nude mice was found (6).  In humans, the DiGeorge syndrome 
has been long considered the prototype of an athymic disorder, even 
though in these patients some mature type T cells are present making 
waver the dogma of the thymus as the unique fundamental organ in T-cell 
ontogeny.  In mice and rats, spontaneous mutations FOXN1 transcription 
factor gene, mapping on chromosome 17, revealed that Foxn1 is essential 
for thymic and skin epithelial differentiation and hence thymopoiesis (7-
9).  In 1966, this athymic animal model was referred as the Nude/SCID 
phenotype due to the presence of congenital alopecia (10-11).  However, 
this spontaneous animal disease profoundly differs in the immunological 
aspects from the human DiGeorge syndrome.  In 1996, the human 
equivalent of the mouse Nude/SCID has been described in a small 
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geographically isolated community in south Italy in 2 sisters with the 
R255X homozygous mutation in FOXN1 gene (12-13).  In this 
community, the identification of a number of heterozygotes for the same 
mutation suggested the need to offer to the population a pre-natal 
diagnosis program for the disease.   
During the genetic counselling, a fetus at risk has been identified.  
FOXN1 gene sequence analysis revealed the homozygous C-to-T 
transition at nucleotide position 792, leading to the nonsense R255X 
mutation.  Protein expression analysis by immunohistochemistry on fetal 
skin fragments revealed the absence of FOXN1 protein as expected on the 
basis of the molecular alteration.  Since in certain circumstances, such as 
immunodeficiencies (14), maternal cells may cross the placenta and 
engraft into the fetus in utero, all samples were analyzed after exclusion of 
maternal cell contamination.  
The study of the immune system in this Nude/SCID fetus gave the 
unique opportunity to gain further insights into the development of T 
lymphocytes in humans in the absence of the thymus and in the absence of 
the FOXN1 transcription factor. 
Because T cells originate from common multipotent HPC, to 
exclude a direct involvement of HPC the presence of CD34+ cells at 
biochemical level was evaluated.  CD34+ cells were comparable to the 
control fetus, 1% of CD45+ hematopoietic cells and, consistently with this, 
no abnormalities in the development of B (65%) and NK (25%) cells were 
found.   
The concomitant assembly of CD4 and CD8 molecules on thymocyte 
surface or their putative individual expression in conjunction with CD3 are 
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markers of discrete stages of T-cell development.  The evaluation of nude 
cord blood cells revealed that the lack of the thymus led to a complete 
absence of CD4+ cells (0.3%) compared to 72% of the control fetus.  
Differently, CD8+ lymphocytes were present (10.3%), although among 
this population cells co-expressing CD3 were considerably low (2.6%), 
whereas CD3+CD8+ in the control were 13.7%.  Of note, approximately 
40% of these cells displayed a naive phenotype as assessed by the 
expression of CD45RA isoform.    
T cells are also distinguished by their cell surface TCRs.  A substantial 
reduction of T cells bearing TCRab (1.6% vs 93% of the control) was 
observed.  Differently, 6.5% of cells expressed TCRgd, but the majority of 
these cells were CD3- cells.  Moreover, 74% of TCR bearing cells 
expressed CD8ab heterodimer.  Again, the diversity of the repertoire was 
ensured at some extent by the few CD8+ cells.  The evaluation of Vb 
usage among CD4+ and CD4- cells revealed that the generation of TCR 
diversity was consistently impaired.  In the CD4+ and CD4- subsets only 3 
and 1 families, respectively, had a gaussian profile.  In the CD4- subset 4 
families predominated, accounting for more than 10% of the total.  In this 
subset, the bV25 was monoclonal and represented 10% of the entire 
repertoire.  As expected, FOXN1-/- cord blood mononuclear cells showed 
absent proliferative response after stimulation with anti-CD3 or 
phytohemagglutinin (PHA). 
To define the extrathymic site of lymphopoiesis of these few CD8+ 
cells, gut mucosa was studied, as the best candidate of primordial 
lymphopoiesis.  In the intestine CD3+ and CD8+ cells but no CD4+ 
lymphocytes in the human athymic fetus were found.  As shown in the 
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figure, CD3+ cells in the gut of FOXN1-/- fetus were normally distributed 
across the gut mucosa, even though not uniformly as expected.  This 
finding argues in favour of a non thymic origin of intestinal lymphocytes.  
This study is ready to be submitted to Nature, due to the importance of 
the finding to study the immune system in humans in the absence of a 
functional thymus.   
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Conclusive Remarks 
 
This study provide a direct evidence of the crucial role of FOXN1 in T-
cell ontogeny in humans, in that its alteration leads to a total blockage of 
CD4+ T-cell maturation and a severe impairment of CD8+ cells with an 
apparent bias toward gd T-cell production.  Since FOXN1 is only 
expressed in the thymus and skin, our data strongly indicate that skin 
epithelial cells play a necessary role in T-cell ontogeny, thus explaining 
the reason of the presence of a considerable number of mature T cells in 
DiGeorge syndrome.  These findings also argue in favour of gut mucosa 
as an extrathymic site of CD8+ cell development, thus confirming former 
observations (15-16).  Remarkably, the development of this subset occurs 
in a thymus independent fashion.  
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§ 4.2     High intrafamilial variability in APECED syndrome: a 
peripheral tolerance study 
 
The genetic cause of many rare autoimmune diseases have been already 
identified and most of these disorders are a result of an intricate 
relationship between environmental and genetic factors, resultant in a 
deregulation of central and peripheral tolerance, that led to auto reactive 
pathogenetic T and B clones.   
The intriguing evidence that the genetic background predisposes to the 
autoimmunity, but it doesn’t define the specific target of the disease, 
demonstrate that there are several factors that influence the phenotypical 
characteristics (17-20). 
Autoimmune Polyendocrinopathy – Candidiasis – Ectodermal - 
Distrophy (APECED; MIM 240300), or autoimmune polyglandular 
syndrome type I, is a rare autosomal recessive disease characterized by a 
set of three abnormal features: chronic mucocoutaneous candidiasis, 
hypoparathyroidism, and adrenal insufficiency.  However, most patients 
also routinely exhibit a variable number of other autoimmune diseases.  
APECED is caused by mutations of a single gene, named autoimmune 
regulator (AIRE), which maps to 21q22.3 (21) and encodes a 55-kDa 
protein that acts as a transcription factor (22).  Animal models of 
APECED have revealed that AIRE plays an important role in T cell 
tolerance induction in the thymus, mainly by promoting ectopic expression 
of a large repertoire of transcripts encoding proteins normally restricted to 
differentiated organs residing in the periphery. Thus, the absence of AIRE 
results in impaired clonal deletion of self-reactive thymocytes (23).  Over 
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60 mutations have by now been localized in the AIRE genes of different 
APECED patients but the different mutations have not to date been 
convincingly associated with particular disease manifestations (23).   
Although the disease is monogenic in transmission, APECED patients 
show a variable range of pathological manifestations, with each patient 
presenting a different constellation of affected organs and auto-antibodies 
specificities.  However, certain targets of the autoimmune attack are near 
constant, such as the adrenal and parathyroid glands, while other 
manifestations are less frequently observed (e.g., thyroiditis or T1D, 
which are present in 2–12% of cases) (24).  Recent analysis have revealed 
that an effect of additional genetic loci, in particular the human leukocyte 
antigen (HLA) complex, is restricted only to few disease manifestations 
(25-26).  Moreover, recent evidences indicate that also a defect in the 
regulatory T cells compartment (Treg) could be involved in the 
pathogenesis of APECED (27).  So far, the reasons of the high 
phenotypical variability of APECED remain still unclear.  
This study was aimed to evaluate whether genetic, immunological and 
environmental factors may be involved in the modulation of the disease in 
two siblings, born from consanguineous parents, with identical genotype 
and extremely different phenotype by studying the exposure to 
infectivological triggers, the HLA aplotype and several mechanisms of 
peripheral tolerance. 
Subjects 
Case 1  
The boy first presented at the age of 5 years with severe asthenia, alopecia, 
and an urticaria-like erythema during a fever.   Physical examination 
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revealed the presence of vitiligo, alopecia, nail dystrophy, oral candidiasis  
hypertransaminasemia and hepatosplenomegaly.  Autoimmune hepatitis 
(AIH) was scored as probable (score 12) on the basis of the 
recommendation of the international AIH group.2 Laboratory 
investigations showed hypocalcaemia (1.3 mmol/l) and 
hyperphosphatemia (2.3 mmol/l) with undetectable levels of PTH, leading 
to the diagnosis of hypoparathyroidism.  He was started on calcium and 
calcitriol therapy.  Over the next three months the patient developed 
autoimmune thyroiditis with severe hypothyroidism (TSH 251 mIU/L, 
Free-T4 6.3 pmol/l) and he started L-Thyroxine therapy.  An increase in 
plasmatic renin levels (216 pg/ml, normal range 1.8-33 pg/ml) in the 
presence of adrenal auto-antibodies, confirmed the diagnosis of adrenal 
insufficiency.  He also presented gastrointestinal symptoms with 
abdominal distension accompanied by alternating diarrhea and 
constipation and presence of auto-antibodies against TPH and AADC, 
commonly associated with gastrointestinal alterations in APECED 
patients.   Atrophic gastritis was diagnosed on the basis of persistently 
elevated levels of gastrinemia (765 pg/ml, normal range 0-80 pg/ml), 
presence of parietal cells Abs (PCA) and histological findings of gastric 
body mucosa atrophy.  
Six months after the onset of this accelerated phase, the patient 
suddenly developed a severe neurological symptomatology with 
neuroradiological findings suggestive of Posterior Reversible 
Encephalopathy Syndrome (PRES), a life-threatening event never 
described before in APECED patients.   
Case 2 
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The girl, the younger sister of case 1, presented at the age of 4 years with 
hypoparathyroidism, diagnosed on the basis of hypocalcaemia, 
hyperphosphatemia and undetectable levels of PTH, and chronic 
mucocutaneous candidasis. No other signs or symptoms of APECED were 
revealed at physical examination or biochemical investigations. During 
her follow-up, through the next two years, she did not develop any other 
features of the disease.  
Direct sequencing of the patients’ AIRE gene revealed in both the 
siblings the presence of the same complex homozygous mutation in intron 
1 consisting of a substitution of IVS1 + 1G by C accompanied by a single 
nucleotide deletion at IVS1 + 5G residue (IVS1 + 1G>C; IVS1 + 5delG).  
The parents were both heterozygous for the same mutation and had no 
features of autoimmunity.  This mutation represents an uncommon 
mutation of AIRE and, so far, has been described in heterozygous state 
with the R257X in a single individual from Poland.  
The direct sequencing of the patients’ AIRE gene revealed in both the 
siblings the presence of the same complex homozygous mutation in intron 
1 consisting of a substitution of IVS1 + 1G by C accompanied by a single 
nucleotide deletion at IVS1 + 5G residue (IVS1 + 1G>C; IVS1 + 5delG).  
The parents were both heterozygous for the same mutation and had no 
features of autoimmunity.  This mutation represents an uncommon 
mutation of AIRE and, so far, has been described in heterozygous state 
with the R257X in a single individual from Poland.  
As previuosly described, circulating auto-antibodies paralleled in each 
patient the clinical phenotype, and strongly supporting the autoimmune 
mechanism at the basis of the pathogenesis of APECED.  Moreover, the 
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evaluation of specific response to infectivological triggers, showed no 
substantial differences that could influence the severity of the disease in 
that the younger sister, which presented a milder phenotype, was more 
exposed to viral infections.  
To define the possible contribution of distinct peripheral tolerance 
mechanisms in the high variability observe in the two patients, we also 
analyzed the resistance to Fas-induced apoptosis and the number of 
CD4+CD25+ cells indicative of the presence of Treg population.  In 
particular, cell death assay after Fas stimulation revealed that the 
resistance to Fas-induced apoptosis was comparable between the siblings 
and normal as in the controls.  Flow cytometric assays revealed a 
comparable number of CD4+CD25+ T cells in the two siblings, but in 
both cases reduced as compared to controls.   
Being NK cells involved in the autoimmunity attributable to failure in 
deletion by cytolitic protein such as Perforin (PRF1), we analyzed NK 
cells activity that resulted comparable to controls in both the cases.  
Moreover, no mutations in the coding region of PRF1 gene were identified 
in both the siblings.  It was notable that the molecular study of the PRF1 
gene disclosed a heterozygous nucleotide substitution in PRF1 exon 3 
resulted in the Ala273Ala silent mutation.  This substitution was only 
found in the Case 1.    
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Conclusive Remarks 
 
Here we reported the case of two siblings affected with APECED that 
showed a high intra familiar variability of phenotype despite the same 
genotype of the AIRE gene.  Although APECED is generally considered a 
monogenic disorder, it is characterized by a wide variability of expression 
with each patient presenting a different constellation of affected organs 
and autoAb specificities. 
As other autoimmunity disease, APECED is the result of alterations at 
different levels, as demonstrated by the remarkable north/south gradient in 
the susceptibility to autoimmune diseases that suggests that environmental 
factors could be involved (28).   
Studies of Aire knockout mice have provided direct evidence that Aire 
has a vital role in preventing autoimmunity.  In particular, APECED 
animal models revealed that Aire plays an important role in T-cell 
tolerance induction in the thymus, mainly by promoting ectopic expression 
of a large repertoire of transcripts encoding proteins normally restricted to 
differentiated organs residing in the periphery.  Thus, the absence of AIRE 
results in impaired clonal deletion of self-reactive thymocytes, which 
escape into the periphery and attack a variety of organs (23).  
The extreme variability of APECED presentation, even between 
siblings with the same genotype, leads to speculate that other mechanisms, 
beyond AIRE itself, could be involved in the clinical expression of the 
disease.  
We observed two siblings patients with the same genetic AIRE 
mutations, but with a spectrum of target organs completely different.  
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Although it is well known that APECED is characterized by extreme 
variability of phenotype, the reasons of this phenomenon remain still 
unclear.  
In particular, being the infectious agents represent a potent stimulus for 
the immune system and may contribute to select auto reactive T cells in 
susceptible subjects, through molecular mimicry (29-31), bystander 
activation (32-33) and epitope spreading (34), we examined the associated 
infections in both patients, but they show an identical infective story.  
Moreover, we analyzed NK activity and eventual genetic alterations in 
PRF1 gene.  The results of this analysis showed a comparable NK activity 
any alterations in PRF1 gene for both patients. It is likely that a not-
screened mutation in the intronic or in the promoter region of PRF1 gene 
could influence the different phenotype observed in the siblings. 
Furthermore, on the other side of the central tolerance there are other 
mechanisms that maintain tolerance to self, such as the induction of 
functional anergy, deletion by apoptosis, and the suppressive actions of 
Treg.  On the bases of these mechanisms we analyzed in particular the 
resistance to apoptosis by cell death assay with Fas, the number and the 
functionality of Treg, attributable to a normal expression of the 
transcription factor Foxp3.  During this analysis we didn’t note any 
variations between the two sibling patients.   
In summary, we found a high intrafamiliar variability in two siblings 
affected with the same mutation of AIRE gene.  The results imply that the 
analyzed mechanisms did not influence the phenotypic spectrum of 
APECED.   
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Technologies 
 
Reagents 
Recombinant human GH (rGH) was obtained from Serono (Saizer 4). The 
enhanced chemiluminescence (ECL) kit was purchased from Amersham 
Biosciences. The Abs anti-gc, anti-JAK3, anti-b-actin, anti-
phosphotyrosine ERK, anti-histone 3 (H3), anti-phosphotyrosine, anti-
STAT5 were purchased from Santa Cruz Biotechnology.  Acrylamide and 
bisacrylamide were obtained from Invitrogen.  Prestained molecular mass 
standards were obtained from Bio-Rad.  The small interfering RNA 
(siRNA) duplexes specific for gc and the control nontargeting siRNA were 
obtained from Invitrogen.  The control nontargeting pool contains 
nontargeting siRNAs with guanine cytosine content comparable to that of 
the functional siRNA but lacking specificity for known gene targets.  The 
Ab anti-JAK2 was purchased from Cell Signaling Technology.  The 
neutralizing IgG1 anti-gc mAb was purchased from R&D Systems. An 
IgG1 isotype-matched anti-CD3 mAb (Leu 3, UCHT1 clone) was 
purchased from BD Biosciences. Epidermal growth factor was purchased 
from BD Biosciences and used at the concentration of 100 ng/ml.  Except 
where noted, other reagents were from Sigma-Aldrich.   
 
Cells and cell cultures 
Mononuclear cells (PBMC) were obtained from four X-SCID patients and 
normal donors and heparinized peripheral blood by Ficoll-Hypaque 
(Biochrom) density gradient centrifugation. Upon informed consent, 
lymphoblastoid cell lines (BCLs) were generated by EBV immortalization 
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of patients and control PBMC using standard procedures. In all cases, gc 
mutations led to the absence of protein expression. Cells were maintained 
in RPMI 1640 (Biochrom) supplemented with 10% FBS (Invitrogen Life 
Technologies), 2 mM/L L-glutamine (Invitrogen Life Technologies), and 
50 microg/ml gentamicin (Invitrogen Life Technologies), and cultured at 
37°C, 5% CO2. In BCL transduction experiments, the pGC2Rg retroviral 
vector was used to transduce X-SCID BCLs with wild-type gc as 
previously described. Transduced cells were selected in the 
neomycinanalog G418 (Cellgro). NIH 3T3 fibroblasts were used in a few 
experiments. 
 
siRNA transfection 
Preparation of the cells before Lipofectamine 2000 transfection was 
performed according to the manufacturer’s recommendations.  Briefly, for 
each transfection 1 X 106 BCLs in 1 ml were treated with 20 microl of 50 
microM of siRNAs specific for the gc or equal amount of the control 
nontargeting siRNA.  The siRNAs were solubilised and formed complexes 
separately with the lipid-based transfectant, Lipofectamine 2000.  The 
siRNA-lipofectamine complexes were transfected into the cultured cells in 
a 24-well plate and incubated for the time indicated in the text.  
Throughout the experiments, cell vitality was monitored continuously by 
trypan blue exclusion assay. Furthermore, 96 h after the transfection, the 
cells were washed, placed in fresh culture medium and used for further 
analysis, as described.       
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Proliferative assay 
BCLs (1x105 cell/200 microl well) were cultured triplicate in 96 well 
Ubottom microtiter plates (Falcon; BD Biosciences) with or without rGH 
at reported concentrations for 4 days. The proliferative response was 
evaluated by thymidine uptake from cultured cells pulsed with 0.5 
microCi of [3H]thymidine (Amersham Biosciences) 8 h before harvesting. 
In neutralization experiments, control EBV cells were preincubated with 
the neutralizing mAb 284 at the concentration of 6 ng/ml for 3 h or with 
the IgG1 isotype-matched Ab (Leu 3).  Where indicated for proliferative 
assay were used common mitogens.   
In self-sufficient growth experiments, BCLs were cultured in 
Dulbecco modified Eagle medium (DMEM)/F12 without FBS and 
supplemented with 2 mM/L L-glutamine.  
 
CFSE labelling 
Cell proliferation was measured by the cell surface stain 
carboxyfluorescein diacetate succinimidyl ester (CFSE).  BCLs (1 X 106) 
were labelled with 1.7 µM CFSE in PBS just before culturing for the 
indicated times.  After 2 min at room temperature, BCLs were washed in 
FBS and phosphate-buffered saline (PBS) and cell division accompanied 
by CFSE dilution was analyzed on a FACS Calibur flow cytometer using 
CellQuest software (Becton Dickinson).   
 
Flow cytometry 
The expression of GHR was detected using specific rabbit Abs (Santa 
Cruz Biotechnology) by indirect immunofluorescence using a second-step 
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incubation with FITC-conjugated donkey anti-rabbit Abs (Pierce). After 
washing in PBS, cells were incubated for 20 min with the specific Abs and 
30 min with secondary Abs. After staining, all samples were washed in 
PBS and acquired on the FACScan flow cytometer (BD Biosciences) 
using Lysis I software. 
 
Cell stimulation and protein extraction 
Before hormone treatment, the cells were made quiescent through 
incubation in RPMI 1640 minus serum for 8–12 h. GH was used at 37°C 
at a concentration of 500 ng/ml in RPMI 1640 for the reported time. 
Incubations were terminated by washing cells with ice-cold PBS 
(BioWhittaker) followed by solubilization in 100 microl of lysis solution 
containing 20 mM Tris (pH 8), 137 mM NaCl, 1% Nonidet P-40, 10 mM 
EDTA, 1 mM PMSF, 1 mM sodium orthovanadatum (Na3VO4), 5 
microg/ml leupeptin, and 5 microg/ml aprotinin. The cell lysates were 
stored at -80°C for Western blot analysis. Nuclear extracts were prepared 
by previous described method and were subsequently mixed with sample 
buffer. 
 
Western blot and immuneprecipitation 
Immunoblotting using phosphotyrosine mAb was performed as previously 
reported. Immunoblotting using specific Ab was performed according to 
the vendor protocols. In brief, protein samples separated by SDS-PAGE 
were transferred onto Mixed Cellulose Esters membranes (Immobilon-NC 
Mixed Cellulose Esters 0.45 _m; Millipore). The membrane was incubated 
at room temperature for 1 h in blocking buffer consisting of 10% BSA in 
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wash buffer (10 mM Tris (pH 7.5), 100 mM NaCl, and 0.1% Tween 20).  
The membrane was then washed three times in wash buffer and incubated 
1 h at room temperature or overnight at 4°C with the specific Ab. The 
membrane was then washed three times and an appropriate IgG 
HRPconjugated secondary Ab was used for the second incubation. After 
further washings, the membrane was developed with ECL-developing 
reagents, and exposed to x-ray films according to the manufacturer’s 
instructions (Amersham Biosciences). 
For immunoprecipitation, lysates were normalized for either 
protein content or cell number and precleared with protein G agarose 
beads (Amersham Biosciences).  The supernatant was incubated with 2 
microg/ml anti-JAK3 or polyclonal serum, followed by protein G agarose 
beads.  The immunoprecipitates were separated on density gradient gels, 
followed by Western blotting.  Proteins were detected using antibody for 
phosphotyrosine.  
 
Confocal microscopy 
After appropriate stimulation, as indicated, cells were fixed in 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.0) for 30 min at room 
temperature and centrifuged in a Shandon Cytospin III (Histotronix) onto 
a glass slide and permeabilized by incubation in a 0.2% Triton X-100 
solution for 20 min.  BCLs were incubated for 1 h at room temperature 
with rabbit anti-STAT5 Ab in PBS containing 1% BSA.  After four 
washings for 5 min in PBS, the cells were incubated for 1 h at room 
temperature with FITC-conjugated donkey anti-rabbit IgG (Pierce) in 
PBS. After washing in PBS, the glass slides were mounted under a 
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coverslip in a 5% glycerol PBS solution. The slides were analyzed by laser 
scanning confocal microscopy using a Zeiss LSM 510 version 2.8 SP1 
Confocal System (Zeiss).  At least 100 cells per condition were analyzed 
in each experiment to determine the rate of STAT5 nuclear translocation. 
 
Genetic counseling 
A genetic counseling program was offered to the village population from 
which the 2 probands affected with the Nude/SCID phenotype were 
originated.  Since FOXN1 mutation is particularly devastating, because it 
leads to the absence of the thymus and SCID, prenatal diagnosis by direct 
genetic analysis was performed for couples at risk.  The genetic 
counseling also included taking a detailed family history and drawing a 
family tree.   
 
Mutational Analysis 
After written informed consent was obtained from parents and upon 
approval of Institutional Ethical Committee, genomic DNA was extracted 
following standard procedures from amniocytes and processed 
anonymously.(Miller, 1988 #1130) This procedure was performed in a 
laboratory with “CLIA certification” and FOXN1 DNA analysis was 
performed according to a polymerase chain reaction assay previously 
described. (Adriani, 2004 #1235) Briefly, a PCR fragment containing exon 
5 of the FOXN1 gene was amplified using the primers: Exon 5F: 5'-
CTTCTGGAGCGCAGGTTGTC-3' and Exon 5R: 5'-
TAAATGAAGCTCCCTCTGGC-3'.  Aliquot of the samples to be studied 
were digested with the restriction enzyme Bsr I and the product was 
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electrophoresed on 1.5% agarose gel.  PCR fragments positive to the 
digestion with Bsr I were then purified on Edge Centriflex columns (Edge 
BioSystems) and sequenced directly with POP-6 polymer using an ABI 
Prism 310 Genetic Analyzer from Applied Biosystems Inc. (Perkin 
Elmer).  After informed consent fetus underwent physical examination by 
our pathologist in order to define whether FOXN1 homozygous alteration 
was associated with defects in the differentiation process and fetus 
development.  
For AIRE mutation analysis genomic DNA was isolated from 
peripheral blood lymphocytes of both patients. Primers were designed to 
amplify each of the 14 exons of the AIRE gene and its intronic flanking 
sequences (GenBank accession no. AB006684). PCR conditions were 
optimized using various magnesium concentrations and annealing 
temperatures.  40 ng of genomic DNA was run in each PCR reaction. PCR 
products were then purified from agarose gel by a QIAquick Gel 
Extraction kit (Qiagen, Hilden, Germany), automatically sequenced using 
Big Dye terminator (Applied Biosystems, Foster City, CA), and then run 
on an ABI 3100 machine (Applied Biosystems). 
 
A-T Patients  
Blood samples were obtained from six consecutive patients (3 males), of 
5, 6, 14, 15, 27 and 29 years of age, respectively (mean age 16.3 years, 
range 5-29 years), affected with A-T.  The patients, upon written consent, 
received a cycle of oral betamethasone at the dosage of 0.1 mg/kg/day for 
10 days divided every 12 hours.  No antioxidants, as N-acetyl cysteine, 
vitamin E or alphalipoic acid, were given to the patients during the two 
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years preceding the trial.  The clinical evaluations were carried out before 
therapy (T0), 48 h from the beginning (T48), at the end of the therapy 
(T10d) and, eventually, 7 days from the withdrawal (T7 off therapy).  The 
neurological evaluation was performed through the Scale for the 
Assessment and Rating of Ataxia (SARA) (see appendix E1 on the 
neurology Web site at 
http://www.neurology.org/cgi/cintent/full/66/11/1717/DC1).  In particular, 
in this study we utilized the variation in SARA Score (D), considering that 
the higher D is the higher amelioration.  Cerebellar atrophy score was 
calculated as follows: 0 score= absence of cerebellar atrophy; 1 score= 
absence of cerebellar atrophy with moderate pontocerebellar angle cisterns 
enlargement; 2 score= moderate atrophy involving mostly both superior 
and inferior portion of the vermis and, at a lesser extent, the cerebellar 
hemispheres with moderate enlargement of periquoral spaces; 3 score= 
severe atrophy of superior portion of vermis and moderate atrophy of 
inferior part of vermis; severe atrophy of superior and lateral portion of 
cerebellar hemispheres and moderate atrophy of inferior hemispheres; 4 
score= global and severe atrophy of the superior and inferior part of 
vermis and the whole cerebellar hemispheres with marked fourth ventricle 
enlargement. 
 
Cell isolation and treatment in redox studies 
Mononuclear cells (PBMC) were obtained from A-T patients and normal 
donors heparinized peripheral blood by Ficoll-Hypaque (Cambrex, Milan, 
Italy) density gradient centrifugation.  Cells were maintained in RPMI 
1640 (Cambrex, Milan, Italy) supplemented with 10% FBS (Cambrex, 
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Milan, Italy), 2mM/L L-glutamine (Invitrogen Life Technologies, Milan, 
Italy), and 50 µg/ml gentamicin (Invitrogen Life Technologies, Milan, 
Italy), and cultured at 37°C, 5% CO2 without stimuli or stimulated for 48 h 
with PHA (8mg/ml) and then collected. 
 
Determination of lipid peroxidation 
Cells (0.8x105) were lysed by freeze and thaw in 10 mM TRIS pH 7.5 and 
the lipid peroxides were assessed with Cayman Chemical Company assay 
kit (Ann Arbor, Michigan, USA), according to the manufacturer’s 
instruction. This kit measures malonaldehyde (MDA) and 4-
hydroxyalkenals that result from peroxidation of polyunsaturated fatty 
acids.  The samples were normalized for cell number. 
 
Evaluation of intracellular glutathione  
The cells were lysed by freeze and thaw. Cellular levels of GSH were 
determined using DIGT-250 GSH colorimetric assay kit (BioAssay 
Systems, California, USA). Cells (0.8x105) were treated for 48 h with 
various agents and collected by centrifugation at 1300 g for 10 min at 4°C.  
All the samples were analyzed following manufacturer’s instructions.  
Optical density (OD)-values were read at 412 nm.  The samples were 
normalized for cell number. 
 
Measurement of intracellular ROS 
The cellular ROS accumulation was measured using the 2′, 7′-
dichlorofluorescein diacetate (DCFH-DA) method.  DCFH-DA is a non-
fluorescent compound, and it can be enzymatically converted to highly 
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fluorescent compound, DCF, in the presence of ROS. After and before 
exposure to betamethasone, 1x106 cells were treated with 5 µM DCFH-
DA at 37°C for 20 min, at 5% CO2, washed with PBS, collected and 
analyzed immediately on a FACScan flow cytometer (Becton Dickinson, 
New Jersey, USA) equipped with an argon laser emitting at 488 nm.  Cell 
Quest software (Becton Dickinson, New Jersey, USA) was used to acquire 
and evaluate all the events. 
 
Cell death assay 
Fas-induced cell death was evaluated, as previously reported, on T-cell 
lines obtained by activating PBMCs with phytohemagglutinin (PHA) at 
days 0 (1 mg/mL) and 13 (0.2 mg/mL) and cultured in RPMI 1640 
medium þ 10% fetal bovine serum (FBS) þ recombinant interleukin-2 
(rIL-2) (2 U/mL) (Biogen). Fas function was assessed at day 19. Cells 
were incubated with control medium or anti-Fas MAb (1 mg/mL) (CH 11 
clone, UBI) in the presence of rIL-2 (2.5 U/mL) to minimize spontaneous 
cell death. Cell survival was evaluated after 18 h by counting live cells in 
each well by trypan blue exclusion test. 
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Summary 
 
The field of the clinical description, genetic characterization, and 
immunological investigation of novel PIDs, born in the 1950s, in the last 
twenty years of the 20th century has revealed a formidable numbers of 
scientific discoveries.  Many scientific papers have been published on the 
molecular and cellular basis of the immune response and on the 
mechanisms involved in the correct ontogeny of immune system 
components.  Although today we know the genetic and molecular basis of 
those principal mechanisms involved in the immune response, this field 
retains a great potential for growth.   
     During the three years of my PhD program I have contributed in some 
measure to clarify some “Novel aspects in Immunodeficiencies”, through 
the combination of clinical, cellular, functional and molecular approaches.    
    In particular, studying a group of atypical patients with X-SCID I 
contributed to demonstrate for the first time a previously unappreciated 
functional interaction between the GHR apparatus and the gc.  
Furthermore, this knowledge helped me to reveal a prior unidentified 
property of the common gc trasducing element.  I could demonstrate, in 
fact, that this subunit is able to influence the cell-cycle progression, 
spontaneous or GH-induced, in a concentration dependent manner.   
     Moreover, I spent my PhD also to better characterize at both molecular 
and clinical levels the human Nude/SCID phenotype.  In this context, I 
could suggest for the first time a functional role of FOXN1 transcription 
factor in the development and differentiation of the central nervous 
system.   
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     In addition, among those PIDs whose causing genes are not selectively 
expressed in the hematopoietic compartment, I contributed to the study 
first of the effects of steroid treatment in patients affected with Ataxia 
telangiectasia, currently without an effective treatment, and after of the 
role of oxidative stress in its beneficial therapy. 
     During my PhD I also paid a particular attention to T-cell ontogeny 
defects affecting both the positive and negative selection processes.  In 
this field I had a unique opportunity to study T-cell development in 
humans in the absence of a functional thymus; this study led to the 
identification of some subsets of T-cell able to mature in extrathymic sites.  
In the context of the negative selection process, I studied the role of 
peripheral tolerance mechanisms in the high phenotypic intra-familiar 
variability existing in the APECED syndrome.   
     Overall, all my studies were designed in order to clarify some unknown 
mechanisms underlying the functionality and the development of the 
immune system well as to study the basis of some regulatory networks 
governing the interactions existing between the immune and other 
systems.    
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Appendix I 
 
Abbreviations 
 
ADA = Adenosine Deaminase  
APC = Antigen Presenting Cells  
A-T = Ataxia Telangiectasia 
ATM = Ataxia Telangiectasia Mutated 
APECED = Autoimmune – Polyendocrinopathy – Candidiasis – Ectodermal Distrophy  
AIRE = AutoImmune REgulator  
BCL = B Cell Line 
BMP = Bone Morphogenetic Proteins 
CSP = Cavum Septum Pellucidum  
CNS = Central Nervous System  
CSF = CerebroSpinal Fluid  
gc = Common Gamma Chain 
DCs = Dendritic Cells  
DSB = Double-Strand Break  
DC = Dyskeratosis Congenita  
FOX = Forkhead bOX  
GS = Glutathione 
PHGPx = Glutathione Peroxidase  
GVHD = Graft-Versus-Host-Disease 
GH = Growth Hormone  
GHR = Growth Hormone Receptor 
HPC = Hematopoietic Precursor Cell 
IKK = IkB Kinase  
IPEX = Immunodysregulation Polyendocrinopathy Enteropathy X-linked  
Ig = Immunoglobulin 
IL = InterLeukin 
IVIG = IntraVenous ImmunoGlobulin 
JAK = Janus Associated Kinase  
KGF = Keratinocyte Growth Factor  
MRI = Magnetic Resonance Imaging  
NK = Natural Killer  
PRF = Perforin 
PI3K = Phosphatidyl Inositol 3 Kinase  
PHA = Phytohemagglutinin 
PID  = Primary ImmunoDeficiency  
PKB, Akt = Protein Kinase B 
ROS = Reactive Oxygen Species  
GSH = Reduced Glutathione 
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Treg = regulatory T lymphocytes  
SARA = Scale for the Assessment and Rating of Ataxia 
SGK = Serum/Glucocorticoid-Regulated Kinase  
SCID = Severe Combined ImmunoDeficiency 
siRNA = Short Interfering RNA  
STAT = Signal Trasducer and Activator of Trascription 
SMAD = Small Mothers Against Decapentaplegic  
SOD = Superoxide Dismutase 1  
SLE = Systemic Lupus Erythematosus 
TCR = T cell Receptor  
TEC = Thymic Epithelial Cell  
TGF = Tumor Growth Factor 
TNF = Tumor Necrosis Factor 
Wnt = Wingless 
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